Literature DB >> 21986286

Isolated atrioventricular block in the fetus: a retrospective, multinational, multicenter study of 175 patients.

Håkan Eliasson1, Sven-Erik Sonesson, Gurleen Sharland, Fredrik Granath, John M Simpson, Julene S Carvalho, Hana Jicinska, Viktor Tomek, Joanna Dangel, Paulo Zielinsky, Maria Respondek-Liberska, Matthias W Freund, Mats Mellander, Joaquim Bartrons, Helena M Gardiner.   

Abstract

BACKGROUND: Isolated complete atrioventricular block in the fetus is a rare but potentially lethal condition in which the effect of steroid treatment on outcome is unclear. The objective of this work was to study risk factors associated with death and the influence of steroid treatment on outcome. METHODS AND
RESULTS: We studied 175 fetuses diagnosed with second- or third-degree atrioventricular block (2000-2007) retrospectively in a multinational, multicenter setting. In 80% of 162 pregnancies with documented antibody status, atrioventricular block was associated with maternal anti-Ro/SSA antibodies. Sixty-seven cases (38%) were treated with fluorinated corticosteroids for a median of 10 weeks (1-21 weeks). Ninety-one percent were alive at birth, and survival in the neonatal period was 93%, similar in steroid-treated and untreated fetuses, regardless of degree of block and/or presence of anti-Ro/SSA. Variables associated with death were gestational age < 20 weeks, ventricular rate ≤ 50 bpm, fetal hydrops, and impaired left ventricular function at diagnosis. The presence of ≥ 1 of these variables was associated with a 10-fold increase in mortality before birth and a 6-fold increase in the neonatal period independently of treatment. Except for a lower gestational age at diagnosis in treated than untreated (23.4 ± 2.9 versus 24.9 ± 4.9 weeks; P=0.02), risk factors were distributed equally between treatment groups. Two-thirds of survivors had a pacemaker by 1 year of age; 8 children developed cardiomyopathy.
CONCLUSIONS: Risk factors associated with a poor outcome were gestation < 20 weeks, ventricular rate ≤ 50 bpm, hydrops, and impaired left ventricular function. No significant effect of treatment with fluorinated corticosteroids was seen.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21986286     DOI: 10.1161/CIRCULATIONAHA.111.041970

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  45 in total

1.  Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus.

Authors:  Peter M Izmirly; Nathalie Costedoat-Chalumeau; Cecilia N Pisoni; Munther A Khamashta; Mimi Y Kim; Amit Saxena; Deborah Friedman; Carolina Llanos; Jean-Charles Piette; Jill P Buyon
Journal:  Circulation       Date:  2012-05-24       Impact factor: 29.690

2.  Serum Biomarkers of Inflammation, Fibrosis, and Cardiac Function in Facilitating Diagnosis, Prognosis, and Treatment of Anti-SSA/Ro-Associated Cardiac Neonatal Lupus.

Authors:  Amit Saxena; Peter M Izmirly; Sung Won Han; Paraskevi Briassouli; Tania L Rivera; Hua Zhong; Deborah M Friedman; Robert M Clancy; Jill P Buyon
Journal:  J Am Coll Cardiol       Date:  2015-08-25       Impact factor: 24.094

Review 3.  Prenatal evaluation and management of fetuses exposed to Anti-SSA/Ro antibodies.

Authors:  Anita Krishnan; Jodi I Pike; Mary T Donofrio
Journal:  Pediatr Cardiol       Date:  2012-05-22       Impact factor: 1.655

Review 4.  Diagnosis and treatment of fetal arrhythmia.

Authors:  Annette Wacker-Gussmann; Janette F Strasburger; Bettina F Cuneo; Ronald T Wakai
Journal:  Am J Perinatol       Date:  2014-05-23       Impact factor: 1.862

Review 5.  Progress in the pathogenesis and treatment of cardiac manifestations of neonatal lupus.

Authors:  Peter Izmirly; Amit Saxena; Jill P Buyon
Journal:  Curr Opin Rheumatol       Date:  2017-09       Impact factor: 5.006

6.  The prevention, screening and treatment of congenital heart block from neonatal lupus: a survey of provider practices.

Authors:  Megan E B Clowse; Amanda M Eudy; Elizabeth Kiernan; Matthew R Williams; Bonnie Bermas; Eliza Chakravarty; Lisa R Sammaritano; Christina D Chambers; Jill Buyon
Journal:  Rheumatology (Oxford)       Date:  2018-07-01       Impact factor: 7.580

7.  Cardiac fibroblast transcriptome analyses support a role for interferogenic, profibrotic, and inflammatory genes in anti-SSA/Ro-associated congenital heart block.

Authors:  Robert M Clancy; Androo J Markham; Tanisha Jackson; Sara E Rasmussen; Miroslav Blumenberg; Jill P Buyon
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-06-16       Impact factor: 4.733

Review 8.  Prenatal diagnosis and management of congenital complete heart block.

Authors:  Jay D Pruetz; Jennifer C Miller; Gerald E Loeb; Michael J Silka; Yaniv Bar-Cohen; Ramen H Chmait
Journal:  Birth Defects Res       Date:  2019-03-01       Impact factor: 2.344

Review 9.  Prevention and treatment in utero of autoimmune-associated congenital heart block.

Authors:  Amit Saxena; Peter M Izmirly; Barbara Mendez; Jill P Buyon; Deborah M Friedman
Journal:  Cardiol Rev       Date:  2014 Nov-Dec       Impact factor: 2.644

Review 10.  Neonatal lupus: advances in understanding pathogenesis and identifying treatments of cardiac disease.

Authors:  Peter M Izmirly; Jill P Buyon; Amit Saxena
Journal:  Curr Opin Rheumatol       Date:  2012-09       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.